Epidemiological and Disease Control Unit, Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium.
PLoS One. 2009 Nov 23;4(11):e7954. doi: 10.1371/journal.pone.0007954.
Standard short course chemotherapy is recommended by the World Health Organization to control tuberculosis worldwide. However, in settings with high drug resistance, first line standard regimens are linked with high treatment failure. We evaluated treatment outcomes after standardized chemotherapy with the WHO recommended category II retreatment regimen in a prison with a high prevalence of drug resistant tuberculosis (TB). A cohort of 233 culture positive TB patients was followed through smear microscopy, culture, drug susceptibility testing and DNA fingerprinting at baseline, after 3 months and at the end of treatment. Overall 172 patients (74%) became culture negative, while 43 (18%) remained positive at the end of treatment. Among those 43 cases, 58% of failures were determined to be due to treatment with an inadequate drug regimen and 42% to either an initial mixed infection or re-infection while under treatment. Overall, drug resistance amplification during treatment occurred in 3.4% of the patient cohort. This study demonstrates that treatment failure is linked to initial drug resistance, that amplification of drug resistance occurs, and that mixed infection and re-infection during standard treatment contribute to treatment failure in confined settings with high prevalence of drug resistance.
世界卫生组织推荐标准短程化疗来控制全球范围内的结核病。然而,在耐药率较高的环境中,一线标准方案与高治疗失败率相关。我们评估了在一个耐药结核病(TB)高发监狱中使用世界卫生组织推荐的 II 类复治方案进行标准化化疗后的治疗结果。对 233 例培养阳性的 TB 患者进行了队列研究,在基线、治疗 3 个月和治疗结束时进行了痰涂片显微镜检查、培养、药敏试验和 DNA 指纹分析。总的来说,172 例患者(74%)培养转阴,而 43 例(18%)在治疗结束时仍为阳性。在这 43 例中,58%的失败病例是由于药物治疗方案不足引起的,42%的失败病例是由于初始混合感染或在治疗过程中再次感染引起的。总的来说,治疗过程中耐药性扩增发生在患者队列的 3.4%。这项研究表明,治疗失败与初始耐药性有关,耐药性的扩增发生,在耐药率较高的封闭环境中,混合感染和治疗期间再次感染也是导致标准治疗失败的原因。